EAM
TRML

Eventide Asset Management’s Tourmaline Bio TRML Stock Holding History

Eventide Asset Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-320,916
Closed -$7.35M – 171
2024
Q1 		$7.35M Buy
+320,916
New +$11.3M 0.12% 130
2023
Q2 		– Sell
-156,109
Closed -$2.93M – 153
2023
Q1 		$2.93M Hold
156,109
– – 0.05% 133
2022
Q4 		$1.59M Hold
156,109
– – 0.03% 135
2022
Q3 		$4.11M Hold
156,109
– – 0.08% 125
2022
Q2 		$7.04M Hold
156,109
– – 0.15% 108
2022
Q1 		$15.4M Hold
156,109
– – 0.24% 97
2021
Q4 		$23.9M Hold
156,109
– – 0.31% 86
2021
Q3 		$20.7M Hold
156,109
– – 0.27% 93
2021
Q2 		$22.4M Buy
+156,109
New +$23.9M 0.3% 88

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Eventide Asset Management's TRML Position: Q2 2024 in Review

Eventide Asset Management sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 320,916 shares — an estimated $7.35M sold.

Eventide Asset Management first reported a position in TRML in Q2 2021 and held it in 9 quarters. The position peaked at $23.9M in Q4 2021. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

  • Eventide Asset Management reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
  • Eventide Asset Management sold 320,916 Tourmaline Bio shares in Q2 2024, an estimated $7.35M.
  • Eventide Asset Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 9 quarters.
  • Eventide Asset Management's Tourmaline Bio position peaked at $23.9M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Eventide Asset Management's 13F filing for Q2 2024, filed 13 Aug 2024.